BioSpace News Archive

Nevro Corp. (NYSE: NVRO) today announced the publication of a consensus statement summarizing recommendations based on outcomes from a December 2022 global, interdisciplinary panel, “Advances in the Management of Painful Diabetic Neuropathy,” at the Worldwide Initiative for Diabetes Education (WorldWIDE Diabetes) Virtual Global Summit.

Gilead Sciences, Inc. announced that Ted Love, MD, has been appointed to the company’s Board of Directors.

BioVaxys Technology Corp. announces that it has completed the first tranche of a non-brokered private placement consisting of 36,783,334 at a price of $0.03 per Unit for total gross proceeds of $1,103,500.

Anbio Biotechnology (“Anbio”), a leading global diagnostic device and assay company, today announced the company will showcase

Takeda announced financial results for the third quarter of fiscal year 2023. With year-to-date strong momentum in its Growth & Launch Products offsetting the significant revenue impact of generic entrants, Takeda remains on track towards its full-year Management Guidance.

Kuros Biosciences, a leader in next generation bone graft technologies, announced it will present at the CG 2024 Musculoskeletal Conference, to be held in San Francisco on February 12, 2024.

Strong pipeline including record 12 blockbuster opportunities under clinical evaluation detailed at recent R&D Day.

François-Xavier Roger will be appointed Chief Financial Officer and a member of Sanofi’s Executive Committee effective April 1, 2024.

Sensorion announces the recruitment of the last patient in its Phase 2a clinical trial of SENS-401 for residual hearing preservation in adult patients following cochlear implantation.

In the 2023 financial year, legacy Novozymes delivers 5% organic sales growth – 6% organic sales growth in the fourth quarter alone – an EBIT-margin before special items[*] of 25.4%, and ROIC including goodwill before special items* of 16.5%.